WALTHAM, Mass.--(BUSINESS WIRE)--Entasis Therapeutics, a clinical-stage biopharmaceutical company focused on the discovery and development of novel antibacterial products, today announced initiation ...

To date, our understanding of the epidemiology of KPC resistance is limited to outbreaks and infections reported from tertiary care academic medical centers. The epidemiology of KPC infections in the ...

Infection Control and Hospital Epidemiology provides original, peer-reviewed scientific articles for anyone involved with an infection control or epidemiology program in a hospital or healthcare ...

Carbapenems have long been a reliable last line of defense in the treatment of infections caused by antimicrobial-resistant Enterobacteriaceae. The emergence of KPC resistance is a major threat to ...